| Not Yet Recruiting | Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function NCT05048368 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Not Yet Recruiting | A Clinical Study of ZL-85FA Tablets NCT07339748 | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 1 / Phase 2 |
| Not Yet Recruiting | Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors NCT06724042 | InSilico Medicine Hong Kong Limited | Phase 1 |
| Not Yet Recruiting | Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors NCT07408258 | OncoC4, Inc. | Phase 1 |
| Not Yet Recruiting | IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors NCT07508761 | Nanjing Immunophage Biotech Co., Ltd | Phase 1 / Phase 2 |
| Not Yet Recruiting | A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors NCT07414836 | BeOne Medicines | Phase 1 |
| Not Yet Recruiting | Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors NCT07512583 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Study in Advanced Solid Tumor Patients NCT07300943 | Callio Therapeutics | Phase 1 / Phase 2 |
| Recruiting | A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advan NCT07380334 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Recruiting | A Study of PLB-002 in Advanced Solid Tumors NCT07304128 | Primelink BioTherapeitics(ShenZhen) Limited | Phase 1 |
| Recruiting | A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour NCT07213830 | Ipsen | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study of MG2512 Injection in Participants With Advanced Solid Tumors NCT07348653 | Shanghai Mabgen Biopharmaceutical Technology Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors NCT07396090 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | N/A |
| Not Yet Recruiting | Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced NCT07086768 | Lei Zheng | Phase 1 |
| Not Yet Recruiting | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors NCT07252661 | AccSalus Biosciences, Inc. | Phase 1 |
| Recruiting | A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 NCT06887348 | Replimune, Inc. | — |
| Recruiting | An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Adv NCT07222267 | BeOne Medicines | Phase 1 |
| Recruiting | A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors NCT07226349 | BeOne Medicines | Phase 1 |
| Recruiting | STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study NCT07269080 | University of Illinois at Chicago | Phase 1 |
| Not Yet Recruiting | A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors NCT07298772 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Withdrawn | Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Ma NCT04294875 | J Ints Bio | EARLY_Phase 1 |
| Recruiting | First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors NCT07284186 | Plexium, Inc. | Phase 1 |
| Recruiting | A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Adv NCT07181681 | BeOne Medicines | Phase 1 |
| Recruiting | A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors NCT07256782 | Qilu Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advan NCT07166601 | EMD Serono Research & Development Institute, Inc. | Phase 1 |
| Recruiting | A Study of DS5361b in Participants With Advanced Solid Tumors NCT07182591 | Daiichi Sankyo | Phase 1 |
| Recruiting | JMT106 Injection in the Treatment of Advanced Solid Tumors NCT07275073 | Shanghai JMT-Bio Inc. | Phase 1 |
| Recruiting | VSV-02 Compassionate Use in Advanced Solid Tumors NCT07260591 | The First Affiliated Hospital of Xinxiang Medical College | Phase 1 |
| Recruiting | A Study of YL242 in Subjects With Advanced Solid Tumors NCT07197827 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies NCT07098299 | Barbara Ann Karmanos Cancer Institute | Phase 1 |
| Recruiting | A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours NCT06682780 | LaNova Medicines Limited | Phase 1 / Phase 2 |
| Not Yet Recruiting | CVL006 Combination Therapy in Advanced Solid Tumors NCT07157956 | Convalife (Shanghai) Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors. NCT05888857 | Institut Bergonié | Phase 2 |
| Not Yet Recruiting | Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors NCT07142837 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Recruiting | Study of GS-5319 in Adults With Solid Tumors NCT07128303 | Gilead Sciences | Phase 1 |
| Recruiting | A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination W NCT07147348 | BioNTech SE | Phase 1 / Phase 2 |
| Recruiting | A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors NCT06973863 | PharmaEngine | Phase 1 |
| Recruiting | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When NCT07070232 | BioNTech SE | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma NCT07107178 | Biotroy Therapeutics | Phase 1 |
| Recruiting | A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors NCT07124117 | OBI Pharma, Inc | Phase 1 / Phase 2 |
| Recruiting | A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors NCT06997029 | Bristol-Myers Squibb | Phase 1 |
| Recruiting | Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors. NCT06173219 | China-Japan Friendship Hospital | Phase 1 / Phase 2 |
| Recruiting | A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors NCT07083323 | Sichuan Huiyu Pharmaceutical Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors NCT06974110 | MOMA Therapeutics | Phase 1 |
| Recruiting | A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors NCT06953323 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors NCT06859762 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1 |
| Recruiting | A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors NCT06992713 | Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | Phase 1 |
| Recruiting | Study of ZG005 in Patients With Advanced Solid Tumors NCT06927687 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 2 |
| Active Not Recruiting | A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors NCT06993116 | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 |
| Terminated | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With NCT06682806 | Prelude Therapeutics | Phase 2 |
| Not Yet Recruiting | Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation NCT06970132 | Shouyao Holdings (Beijing) Co. LTD | Phase 1 / Phase 2 |
| Recruiting | Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors NCT06938880 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Recruiting | A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients NCT06911827 | Qilu Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors NCT06952010 | Exelixis | Phase 1 |
| Recruiting | A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors NCT06669975 | AP Biosciences Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advan NCT07172802 | GI Innovation, Inc. | Phase 1 / Phase 2 |
| Recruiting | a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors NCT06878612 | Xingchen Peng | Phase 1 |
| Not Yet Recruiting | Phase I Study of HS-20108 in Participants With Advanced Solid Tumors NCT06936735 | Hansoh BioMedical R&D Company | Phase 1 |
| Recruiting | Clinical Studies for the Treatment of Advanced Solid Tumors NCT06825494 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced T NCT06487624 | FBD Biologics Limited | Phase 1 |
| Not Yet Recruiting | A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors NCT06872580 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With A NCT06657144 | Coherus Oncology, Inc. | Phase 1 |
| Not Yet Recruiting | A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours NCT06873854 | LaNova Medicines Limited | Phase 2 |
| Recruiting | Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tu NCT06635785 | OncoC4, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors NCT06803680 | BeiGene | Phase 1 |
| Recruiting | A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours NCT06833008 | Ipsen | Phase 1 / Phase 2 |
| Recruiting | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation NCT06778863 | Clasp Therapeutics, Inc. | Phase 1 |
| Recruiting | A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors NCT06716619 | Guangzhou FineImmune Biotechnology Co., LTD. | Phase 1 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Parti NCT06707610 | Shanghai Allink Biotherapeutics Co., Ltd. | Phase 1 |
| Recruiting | ARC101 in Advanced Solid Tumors NCT06672185 | Third Arc Bio | Phase 1 |
| Not Yet Recruiting | A Study of AK-1286 in Patients With Advanced Solid Tumors NCT06779045 | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 |
| Recruiting | Intramuscular ACM-CpG Monotherapy in Patients With Advanced/Metastatic Solid Tumors With Prior Response to Imm NCT06587295 | National Cancer Centre, Singapore | Phase 1 |
| Recruiting | Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors NCT06750185 | BioNTech SE | Phase 1 |
| Recruiting | A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Parti NCT06772415 | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) NCT06660654 | Daiichi Sankyo | Phase 2 |
| Recruiting | Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors NCT06566079 | InSilico Medicine Hong Kong Limited | Phase 1 |
| Recruiting | APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced S NCT06687070 | Ascentage Pharma Group Inc. | Phase 1 |
| Recruiting | A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug C NCT06625593 | BeOne Medicines | Phase 1 |
| Not Yet Recruiting | Subjects With Advanced or Metastatic Solid Tumor Malignancies NCT05474859 | Xenthera, Inc. | Phase 1 |
| Recruiting | ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours NCT06597721 | Adcendo ApS | Phase 1 |
| Recruiting | A Study of ES014 in Subjects With Advanced Solid Tumors NCT06543056 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration NCT06959615 | Jacobio Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Clinical Study of CVL006 Injection in Advanced Solid Tumors NCT06621615 | Convalife (Shanghai) Co., Ltd. | Phase 1 |
| Withdrawn | A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and NCT05828303 | Turning Point Therapeutics, Inc. | Phase 1 |
| Terminated | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors NCT06685068 | Genmab | Phase 1 / Phase 2 |
| Recruiting | Anti-GD2 ADC M3554 in Advanced Solid Tumors NCT06641908 | EMD Serono Research & Development Institute, Inc. | Phase 1 |
| Recruiting | An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1). NCT06634849 | Pathios Therapeutics Pty Ltd | Phase 1 / Phase 2 |
| Terminated | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMAR NCT06560645 | Prelude Therapeutics | Phase 1 |
| Recruiting | A Study of the ILB-3101 in Patients with Advanced Solid Tumors NCT06426680 | Innolake Biopharm | Phase 1 |
| Active Not Recruiting | A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors NCT06607185 | Eli Lilly and Company | Phase 1 |
| Recruiting | Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tu NCT06598800 | BeiGene | Phase 1 |
| Recruiting | A Clinical Study of [225Ac]Ac-FAPI-XT(XT117) Injection in Patients With Advanced Solid Tumors NCT07135128 | Xiaorong Sun | Phase 1 |
| Recruiting | A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors NCT06533332 | EtiraRx Australia Pty Ltd | Phase 1 |
| Recruiting | An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participa NCT06589596 | BeOne Medicines | Phase 1 |
| Terminated | M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Ca NCT06509906 | EMD Serono Research & Development Institute, Inc. | Phase 1 |
| Recruiting | A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Im NCT06577194 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Withdrawn | Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis NCT06365918 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors NCT06561685 | Eli Lilly and Company | Phase 1 |
| Recruiting | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957 | NiKang Therapeutics, Inc. | Phase 1 |
| Terminated | Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors NCT06560632 | Repare Therapeutics | Phase 1 |
| Terminated | A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic So NCT06540066 | BeiGene | Phase 1 |
| Recruiting | EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors NCT06525298 | Eisbach Bio GmbH | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of TTX-MC138 in Subjects With Advanced Solid Tumors NCT06260774 | TransCode Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Study of AXT-1003 in Subjects With Advanced Malignant Tumors. NCT06484985 | Axter Therapeutics (Beijing) Co., Ltd | Phase 1 |
| Recruiting | An Exploratory Study of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Advanced Solid Tumor Treatme NCT06497010 | The Affiliated Hospital Of Guizhou Medical University | EARLY_Phase 1 |
| Recruiting | Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors NCT06352359 | OncoC4, Inc. | Phase 1 |
| Recruiting | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369 | 7 Hills Pharma, LLC | Phase 1 / Phase 2 |
| Recruiting | A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors NCT06533059 | Alterome Therapeutics, Inc. | Phase 1 |
| Recruiting | A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors NCT07110883 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1 |
| Recruiting | Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies NCT06577987 | Circle Pharma | Phase 1 |
| Active Not Recruiting | Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors NCT06545942 | MOMA Therapeutics | Phase 1 |
| Not Yet Recruiting | Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations NCT06519110 | Convalife (Shanghai) Co., Ltd. | Phase 2 |
| Active Not Recruiting | M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) NCT06421935 | EMD Serono Research & Development Institute, Inc. | Phase 1 |
| Recruiting | A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors. NCT06487455 | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1 |
| Recruiting | γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors NCT06404281 | Changzhou No.2 People's Hospital | Phase 1 |
| Recruiting | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours NCT06147037 | AstraZeneca | Phase 1 |
| Recruiting | SW-682 in Advanced Solid Tumors NCT06251310 | SpringWorks Therapeutics, Inc. | Phase 1 |
| Recruiting | A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients. NCT06512116 | Shanghai Institute Of Biological Products | Phase 1 |
| Recruiting | TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies NCT06484816 | Shenzhen TargetRx Co., Ltd. | Phase 1 |
| Active Not Recruiting | A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced So NCT06422520 | BeOne Medicines | Phase 1 |
| Recruiting | Trial of INI-4001 in Patients With Advanced Solid Tumours NCT06302426 | Inimmune Corporation | Phase 1 |
| Active Not Recruiting | A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Soli NCT06470763 | Anaveon AG | Phase 1 / Phase 2 |
| Recruiting | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors NCT06465069 | Eli Lilly and Company | Phase 1 |
| Terminated | A Study of PHN-010 in Patients With Advanced Solid Tumors NCT06457997 | Pheon Therapeutics | Phase 1 |
| Not Yet Recruiting | Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors NCT06446388 | Qilu Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | CAN1012 Combined With PD-1 in Patients With Solid Tumors NCT06410703 | Canwell Biotech Limited | Phase 1 / Phase 2 |
| Recruiting | Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recu NCT06408688 | University Hospital, Basel, Switzerland | Phase 4 |
| Recruiting | Study of SGR-3515 In Participants With Advanced Solid Tumors. NCT06463340 | Schrödinger, Inc. | Phase 1 |
| Recruiting | Study of APR-1051 in Patients With Advanced Solid Tumors NCT06260514 | Aprea Therapeutics | Phase 1 |
| Active Not Recruiting | A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors NCT06480240 | OBI Pharma, Inc | Phase 1 / Phase 2 |
| Recruiting | MAQ-001 in Patients With Advanced Solid Tumors NCT06514651 | MabQuest SA | Phase 1 |
| Recruiting | A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) NCT06277219 | Latticon Antibody Therapeutics, Inc | Phase 1 / Phase 2 |
| Recruiting | Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy NCT06490068 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Withdrawn | Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841 NCT06219499 | OncoC4, Inc. | Phase 1 |
| Recruiting | A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors NCT06037317 | Shouyao Holdings (Beijing) Co. LTD | Phase 1 |
| Active Not Recruiting | QTX3046 in Patients With KRAS G12D Mutations NCT06428500 | Quanta Therapeutics | Phase 1 |
| Terminated | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (M NCT06287463 | Deciphera Pharmaceuticals, LLC | Phase 1 |
| Recruiting | A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors NCT06413615 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients. NCT06298058 | Shanghai Institute Of Biological Products | Phase 1 |
| Recruiting | A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors NCT06431243 | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination NCT06249048 | Strand Therapeutics Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Implementation of Liquid Biopsies During Routine Clinical Care in Patients With Advanced Malignancies (LIQPLAT NCT06367751 | University Hospital, Basel, Switzerland | N/A |
| Recruiting | A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer NCT06163391 | SOTIO Biotech AG | Phase 1 |
| Active Not Recruiting | A Machine Learning-based Estimated Survival Model NCT06432283 | Zhao Siyao | — |
| Not Yet Recruiting | Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage So NCT06363201 | Catalysis SL | N/A |
| Recruiting | ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors NCT06332170 | Hansoh BioMedical R&D Company | Phase 1 |
| Not Yet Recruiting | A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors NCT06383507 | Zhejiang University | Phase 1 |
| Recruiting | Pemigatinib + Afatinib in Advanced Refractory Solid Tumors NCT06302621 | Massachusetts General Hospital | Phase 1 |
| Active Not Recruiting | A Study of MHB039A for Advanced Solid Tumor NCT06345482 | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1 / Phase 2 |
| Recruiting | Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patie NCT06233942 | BeOne Medicines | Phase 1 |
| Active Not Recruiting | A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors NCT06328673 | D2M Biotherapeutics Inc. | Phase 1 |
| Recruiting | A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors NCT06257680 | Aeonvital Biomedicine | Phase 1 |
| Recruiting | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors NCT05932862 | Exelixis | Phase 1 |
| Active Not Recruiting | BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and O NCT06253195 | BeiGene | Phase 1 |
| Recruiting | A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Adva NCT06307925 | HC Biopharma Inc. | Phase 1 |
| Recruiting | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors NCT05983523 | PharmaEngine | Phase 1 |
| Unknown | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (M NCT05872867 | Wellmarker Bio | Phase 1 |
| Active Not Recruiting | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors NCT06334432 | Nuvation Bio Inc. | Phase 1 / Phase 2 |
| Terminated | A Study of BRY805 in Participants With Advanced Solid Tumors NCT06289894 | BioRay Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors. NCT06240546 | Luye Pharma Group Ltd. | Phase 1 |
| Recruiting | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors NCT06257264 | BeiGene | Phase 1 |
| Recruiting | A Study of NBL-028 in Patients With Advanced Solid Tumors NCT06223256 | NovaRock Biotherapeutics, Ltd | Phase 1 |
| Recruiting | A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470 | MacroGenics | Phase 1 |
| Unknown | Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Pati NCT06139536 | Bio-Thera Solutions | Phase 1 |
| Active Not Recruiting | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors NCT06238479 | Eli Lilly and Company | Phase 1 |
| Completed | A Food Effect Study of SPH5030 Tablets. NCT06372223 | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1 |
| Not Yet Recruiting | Study of HS-20105 for Injection in Patients With Advanced Solid Tumors. NCT06144723 | Hansoh BioMedical R&D Company | Phase 1 / Phase 2 |
| Recruiting | A Study of HC006 in Subjects With Advanced Solid Tumors NCT06304571 | HC Biopharma Inc. | Phase 1 |
| Recruiting | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors NCT06172478 | Daiichi Sankyo | Phase 2 |
| Terminated | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | SNV1521 in Participants With Advanced Solid Tumors NCT06220864 | Synnovation Therapeutics, Inc. | Phase 1 |
| Recruiting | TR128 in Patients With Advanced Solid Tumors NCT05751356 | Tarapeutics Science Inc. | Phase 1 |
| Terminated | Phase I Study of RiMO-401 With Radiation in Advanced Tumors NCT06182579 | Coordination Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors NCT06244485 | Daiichi Sankyo | Phase 1 |
| Terminated | LIONS (PLK4 Inhibitor in Advanced Solid Tumors) NCT06232408 | Repare Therapeutics | Phase 1 |
| Recruiting | HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors NCT06112704 | Hansoh BioMedical R&D Company | Phase 2 |
| Enrolling By Invitation | An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid NCT06169579 | Shenzhen NewDEL Biotech, Co., Ltd | Phase 1 |
| Recruiting | Study SC-101 in Subjects With Advanced Malignancies NCT06220838 | Tianjin ConjuStar Biologics Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 G NCT06237881 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study of Simmitinib Plus SG001 in Advanced Solid Tumors NCT06132217 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Phase 1 / Phase 2 |
| Terminated | Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib NCT06130254 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Clinical Trial of BT02 in Patients With Advanced Solid Tumors NCT06404905 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 |
| Recruiting | Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors NCT06171750 | Ankyra Therapeutics, Inc | Phase 1 |
| Recruiting | A Study of KK2269 in Adult Participants With Solid Tumors NCT06266299 | Kyowa Kirin Co., Ltd. | Phase 1 |
| Terminated | JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors NCT06226766 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1 / Phase 2 |
| Completed | Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects NCT06198556 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Recruiting | FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors NCT06241456 | Fate Therapeutics | Phase 1 |
| Recruiting | A Study of NWY001 in Subjects With Advanced Solid Tumors NCT05979155 | Chipscreen Biosciences, Ltd. | Phase 1 |
| Recruiting | A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors NCT06139211 | Shanghai Junshi Bioscience Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours NCT06247657 | Shanghai Best-Link Bioscience, LLC | Phase 1 |
| Recruiting | Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors NCT06084286 | Sichuan University | Phase 1 |
| Recruiting | A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors NCT06211647 | Ruimin Wang | Phase 1 |
| Recruiting | A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors NCT06197139 | Xinlu Wang | Phase 1 |
| Recruiting | MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors NCT06170294 | Peking University | Phase 1 |
| Unknown | A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors NCT04947033 | I-Mab Biopharma US Limited | Phase 1 |
| Recruiting | The Efficacy and Safety of IBI363 in Solid Tumors NCT06081907 | Hunan Province Tumor Hospital | Phase 1 / Phase 2 |
| Recruiting | A Study of LM-24C5 For Advanced Solid Tumors NCT06187402 | LaNova Medicines Limited | Phase 1 / Phase 2 |
| Recruiting | Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumor NCT05916248 | Ruijin Hospital | EARLY_Phase 1 |
| Unknown | A Study of HY-0102 in Patients With Advanced Solid Tumors NCT06094777 | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 |
| Recruiting | A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 NCT05761223 | 1ST Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors NCT06035744 | Cullinan Therapeutics Inc. | Phase 1 |
| Recruiting | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors NCT06253130 | Eikon Therapeutics | Phase 1 / Phase 2 |
| Recruiting | A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer NCT06005740 | TORL Biotherapeutics, LLC | Phase 1 |
| Recruiting | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Soli NCT06120283 | BeOne Medicines | Phase 1 |
| Withdrawn | ATI-2231 in Advanced Solid Tumor Malignancies NCT05791474 | Washington University School of Medicine | Phase 1 |
| Recruiting | FIH XON7 in Advanced/Metastatic Solid Tumors NCT06154291 | Xenothera SAS | Phase 1 / Phase 2 |
| Recruiting | A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors NCT06126666 | ABL Bio, Inc. | Phase 1 |
| Recruiting | JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastat NCT06108050 | Jazz Pharmaceuticals | Phase 1 |
| Active Not Recruiting | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Adva NCT06403436 | TOLREMO therapeutics AG | Phase 1 |
| Recruiting | AMT-253 in Patients With Selected Advanced Solid Tumours NCT05906862 | Multitude Therapeutics (Australia) Pty Ltd | Phase 1 |
| Recruiting | Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibit NCT05901285 | Vaxiion Therapeutics | Phase 1 |
| Recruiting | Study of TRX-920 for Patients With Advanced Solid Tumors NCT06143774 | TaiRx, Inc. | Phase 1 |
| Active Not Recruiting | A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Na NCT05879822 | Incyte Corporation | Phase 2 |
| Recruiting | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers NCT05873686 | Nuvectis Pharma, Inc. | Phase 1 |
| Recruiting | An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of NCT06225856 | Shanghai Yuyao Biotech Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors NCT06143007 | Broadenbio Ltd., Co. | Phase 1 |
| Unknown | Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent NCT06075849 | Panolos Bioscience | Phase 1 |
| Recruiting | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents NCT06090266 | OncoResponse, Inc. | Phase 1 / Phase 2 |
| Unknown | Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors NCT05886868 | Shanghai Best-Link Bioscience, LLC | Phase 1 |
| Recruiting | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer NCT05902988 | Volastra Therapeutics, Inc. | Phase 1 / Phase 2 |
| Enrolling By Invitation | A Phase I Clinical Trial to Evaluate LIT-00814 Tablets in Patients With Advanced Solid Tumor NCT06205082 | LittDD Medicines Ltd | Phase 1 |
| Not Yet Recruiting | PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors NCT06078670 | Fujian Cancer Hospital | Phase 1 / Phase 2 |
| Recruiting | A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematologic NCT05892718 | FBD Biologics Limited | Phase 1 |
| Not Yet Recruiting | A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors NCT05924906 | Suzhou Neologics Bioscience Co., Ltd. | Phase 1 |
| Recruiting | Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors NCT06072989 | Shanghai East Hospital | Phase 1 |
| Active Not Recruiting | First in Human Study of TORL-3-600 in Participants With Advanced Cancer NCT05948826 | TORL Biotherapeutics, LLC | Phase 1 |
| Unknown | A Study of YL-17231 in Patients With Advanced Solid Tumors NCT06078800 | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 |
| Completed | A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors NCT06007482 | Elpiscience Biopharma Australia Pty. Ltd. | Phase 1 |
| Active Not Recruiting | A Study YL201 in Patients With Selected Advanced Solid Tumors NCT06057922 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid NCT05981703 | BeOne Medicines | Phase 1 |
| Terminated | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer NCT05756907 | Sonnet BioTherapeutics | Phase 1 / Phase 2 |
| Recruiting | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types NCT05877430 | CJ Bioscience, Inc. | Phase 1 / Phase 2 |
| Terminated | Study of ART0380 in Patients With Biologically Selected Solid Tumors NCT05798611 | Artios Pharma Ltd | Phase 2 |
| Unknown | Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors NCT06054932 | Beijing Likang Life Science and Tech Co., Ltd. | Phase 1 |
| Unknown | A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors NCT06008366 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors NCT05944185 | Shanghai Cell Therapy Group Co.,Ltd | Phase 1 / Phase 2 |
| Recruiting | Study of AVZO-021 in Patients With Advanced Solid Tumors NCT05867251 | Avenzo Therapeutics, Inc. | Phase 1 / Phase 2 |
| Unknown | A Study of 7MW3711 in Subjects With Advanced Solid Tumors NCT06008379 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors NCT05990452 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors NCT05978102 | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Phase 1 / Phase 2 |
| Completed | Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractor NCT05990920 | NKGen Biotech, Inc. | Phase 1 |
| Completed | PBMC-based Leukocyte Immunotherapy NCT06172894 | invIOs GmbH | Phase 1 |
| Terminated | BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors NCT05935098 | BeiGene | Phase 1 |
| Recruiting | First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors NCT05875168 | Daiichi Sankyo | Phase 1 / Phase 2 |
| Recruiting | A Study of DB-1310 in Advanced/Metastatic Solid Tumors NCT05785741 | DualityBio Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of BA1202 in Patients With Advanced Solid Tumors NCT05909241 | Shandong Boan Biotechnology Co., Ltd | Phase 1 |
| Unknown | A Study of QLF3108 in Participants With Advanced Solid Tumor NCT06019013 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation NCT06006793 | Shouyao Holdings (Beijing) Co. LTD | Phase 1 |
| Recruiting | Study of ZG0895.HCl in Patients With Advanced Solid Tumors NCT05877664 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 |
| Terminated | A Study of DS-1471a In Subjects With Advanced Solid Tumors NCT06074705 | Daiichi Sankyo Co., Ltd. | Phase 1 |
| Recruiting | A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid T NCT06038396 | RemeGen Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study to Investigate FP002 in Subjects With Advanced Malignancies NCT05982080 | Guangdong Fapon Biopharma Inc. | Phase 1 |
| Recruiting | A Study of EOC237 in Patients With Advanced Solid Tumor NCT05895825 | Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd | Phase 1 |
| Recruiting | AMT-116 in Patients With Advanced Solid Tumors NCT05725291 | Multitude Therapeutics Inc. | Phase 1 |
| Recruiting | Safety of AM-928 Infusion in Advanced Solid Tumors NCT05687682 | AcadeMab Biomedical Inc. | Phase 1 |
| Not Yet Recruiting | Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor NCT05933668 | Peking University | Phase 1 |
| Active Not Recruiting | Study of ART6043 in Advanced/Metastatic Solid Tumors Patients NCT05898399 | Artios Pharma Ltd | Phase 1 / Phase 2 |
| Unknown | Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors NCT05884801 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | A Study of DB-1202 Monotherapy in Advanced Solid Tumors NCT05785728 | DualityBio Inc. | Phase 1 / Phase 2 |
| Unknown | Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors NCT05915481 | Peking University Third Hospital | Phase 1 / Phase 2 |
| Unknown | A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Ref NCT06047860 | Second Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer NCT05491083 | National University Hospital, Singapore | Phase 1 / Phase 2 |
| Unknown | Tolerability of Utidelone Capsule in Patients With Advanced Solid Tumors NCT05681000 | Biostar Pharma, Inc. | Phase 1 |
| Recruiting | Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors NCT05700084 | Beijing Biostar Pharmaceuticals Co., Ltd. | Phase 1 |
| Recruiting | Study of LP-184 in Patients With Advanced Solid Tumors NCT05933265 | Lantern Pharma Inc. | Phase 1 / Phase 2 |
| Recruiting | Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors NCT06302062 | Guangzhou FineImmune Biotechnology Co., LTD. | Phase 1 |
| Active Not Recruiting | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid NCT05864144 | Sensei Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Co NCT05824975 | GI Innovation, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors NCT05765851 | Daiichi Sankyo | Phase 1 |
| Terminated | TIL for Patients With Advanced Solid Tumor NCT06334783 | Hervor Therapeutics | Phase 1 |
| Recruiting | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Seque NCT06028724 | Centro di Riferimento Oncologico - Aviano | — |
| Active Not Recruiting | A Study of MHB036C for Advanced Solid Tumor NCT06373406 | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1 / Phase 2 |
| Recruiting | 64Cu-GRIP B in Patients With Advanced Malignancies NCT05888532 | Rahul Aggarwal | Phase 1 / Phase 2 |
| Recruiting | Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors NCT05868174 | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 1 |
| Withdrawn | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss NCT06090318 | Rain Oncology Inc | Phase 1 / Phase 2 |
| Recruiting | The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors NCT05836948 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | XTX301 in Patients With Advanced Solid Tumors NCT05684965 | Xilio Development, Inc. | Phase 1 / Phase 2 |
| Completed | PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 M NCT05639751 | Prelude Therapeutics | Phase 1 |
| Unknown | A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tu NCT05824663 | Harbour BioMed US, Inc. | Phase 1 |
| Unknown | A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors NCT05794477 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Clinical Trial of PM54 in Advanced Solid Tumors Patients. NCT05841563 | PharmaMar | Phase 1 |
| Terminated | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tum NCT05757492 | Coherus Oncology, Inc. | Phase 1 |
| Recruiting | A Study of BPI-460372 in Advanced Solid Tumor Patients NCT05789602 | Betta Pharmaceuticals Co., Ltd. | Phase 1 |
| Recruiting | TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors NCT05650580 | Tarapeutics Science Inc. | Phase 1 |
| Withdrawn | A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid T NCT05381935 | Elpiscience Biopharma, Ltd. | Phase 1 |
| Recruiting | Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor NCT05103345 | Guangzhou Sinogen Pharmaceutical Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors NCT05819684 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid NCT06299124 | Regor Pharmaceuticals Inc. | Phase 1 |
| Unknown | A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors NCT05829616 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors NCT05908773 | TransCode Therapeutics | EARLY_Phase 1 |
| Unknown | A Study of IMC008 for Advanced Solid Tumors NCT05837299 | Changhai Hospital | Phase 1 |
| Unknown | Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors NCT05790447 | Second Affiliated Hospital of Soochow University | Phase 2 |
| Not Yet Recruiting | A Study of KM602 in Patients With Advanced Solid Tumors NCT05766527 | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of TIL in Advanced Solid Tumors (DFGD) NCT06488950 | Shanghai Juncell Therapeutics | EARLY_Phase 1 |
| Terminated | Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors. NCT05831995 | ABM Therapeutics Corporation | Phase 1 |
| Terminated | A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid NCT05821777 | Centessa Pharmaceuticals (UK) Limited | Phase 1 / Phase 2 |
| Recruiting | A Study of XZB-0004 in Patients With Solid Tumors NCT05772455 | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 |
| Unknown | IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors NCT05780307 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase 1 |
| Active Not Recruiting | Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors NCT05744427 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | A Study of PYX-201 in Advanced Solid Tumors NCT05720117 | Pyxis Oncology, Inc | Phase 1 |